Diversified healthcare company CVS Health (NYSE: CVS) reported revenue ahead of Wall Street’s expectations in Q3 2026, with sales up 5.4% year on year to $108.4 billion. The company’s full-year revenue guidance of $420 billion at the midpoint came in 0.5% above analysts’ estimates. Its non-GAAP profit of $2.09 per share was 26.6% above analysts’ consensus estimates.
Is now the time to buy CVS? Find out in our full research report (it’s free for active Edge members).
CVS Health (CVS) Q3 2026 highlights:
- Revenue $108.4 billion vs S&P analysts’ estimates of $104.2 billion (5.4% year-on-year growth, 4.1% beat)
- Adjusted EPS $2.09 vs S&P analysts’ estimates of $1.65 (26.6% beat)
- Adjusted operating income $4.19 billion vs analyst estimates of $3.60 billion (3.9% margin, 16.5% beat)
- Adjusted EPS guidance Management raised its full-year adjusted EPS guidance to $8.20 at the midpoint, a 2.5% increase
- Operating margin 3.3%, up from -3.1% in the same quarter last year
- Locations 8,904.4 at quarter end, down from 9,014 in the same quarter last year
- Same-store sales were flat year on year (14.3% in the same quarter last year)
- Market capitalization $102.3 billion
StockStory’s take
CVS Health’s latest quarter saw the company deliver revenue and profit above Wall Street’s expectations, but the market responded negatively. Management pointed to consistent gains in its core segments, driven by pharmacy strength and progress in Medicare margin recovery. CEO David Joyner highlighted the quarter as "another demonstration of disciplined execution," emphasizing ongoing improvement in the company’s medical benefit ratio and strong cash flow generation.
Looking ahead, CVS Health’s new guidance is anchored by an anticipated split of the company into two independent public entities: a healthcare solutions business and a retail pharmacy company. Management believes this separation will allow both organizations to focus on their core strengths, with CEO David Joyner stating the move is "designed to create greater flexibility, tailored capital allocation, and more effective adaptation to evolving healthcare demands." The company expects the transition to lay the foundation for long-term earnings growth and improved consumer engagement.
Key insights from management’s remarks
CVS Health’s management linked the quarter’s performance to pharmacy volume growth, Medicare improvement, and technology investment, while also announcing a major corporate reorganization.
- Separation into two companies: CVS Health announced plans to split into two independent public companies—a healthcare solutions business (retaining Aetna, Caremark, specialty pharmacy, Oak Street, and Signify Health) and a national retail pharmacy company (including retail stores, mail order, MinuteClinic, and Health100 platform). Management expects the separation to be completed in the first half of 2028.
- Pharmacy segment momentum: Strong prescription growth, particularly in newer drug classes like GLP-1s (glucagon-like peptide-1 receptor agonists used for diabetes and weight loss), drove higher core pharmacy volumes. Management noted a 23% increase in GLP-1 scripts and ongoing investment in technology to streamline pharmacy workflows.
- Medicare margin recovery: The healthcare benefits segment made further progress toward target margins, with the medical benefit ratio (a measure of claims paid relative to premiums collected) improving due to cost management and disciplined pricing, especially in Medicare Advantage.
- Technology and AI investments: CVS Health continued embedding artificial intelligence throughout its businesses, including pharmacy operations and the Health100 consumer engagement platform. Management believes these efforts are simplifying the healthcare experience and positioning the company for future growth.
- Specialty pharmacy and PBM integration: Management reiterated the importance of keeping specialty pharmacy within the healthcare solutions company to address rising drug costs and high-acuity populations. They cited ongoing strength in specialty and the value of integrated pharmacy benefit management (PBM) in controlling total healthcare costs.
Drivers of future performance
Management sees the upcoming company separation, ongoing Medicare improvements, and technology integration as the main themes shaping guidance for the next year.
- Separation to drive focus: The planned split is expected to give each business unit clearer strategic priorities and tailored capital allocation. Management believes this will increase agility, simplify operations, and support more targeted investment in growth areas for both companies.
- Medicare and specialty momentum: CVS Health anticipates continued margin recovery in Medicare Advantage, benefiting from repricing, product mix optimization, and medical cost management. Specialty pharmacy is expected to remain a key growth driver, with management highlighting investments aimed at better serving high-cost patient populations.
- Technology-driven efficiency: Management emphasized that expanded use of AI and digital platforms like Health100 will enhance consumer engagement, improve operational efficiency, and support the launch of new healthcare services. However, leadership acknowledged that transitioning to independent operations will involve some one-time costs and potential dis-synergies.
Catalysts in upcoming quarters
In coming quarters, the StockStory analyst team will be watching (1) the progress and milestones toward the planned company separation, (2) ongoing improvement in Medicare margins and management of 340B program headwinds, and (3) adoption and consumer traction for the Health100 digital platform. We will also closely monitor specialty pharmacy growth and how both entities prepare for independent operations.
CVS Health currently trades at $80.42, down from $91.60 just before the earnings. At this price, is it a buy or sell? See for yourself in our full research report (it’s free).
Stocks that trumped tariffs
ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI is taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.
Our AI system flagged Palantir before it ran 1,662% between October 2022 and February 2026. AppLovin before it ran 753% between February 2024 and February 2026. Nvidia before it ran 1,178% between January 2023 and February 2026. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,552% between June 2020 and June 2025). Find your next big winner with StockStory today.
